Patient, disease, and procedure characteristics according to early T-ICAHT grade
| . | Overall . | Early T-ICAHT . | P value . | ||
|---|---|---|---|---|---|
| Grade 0 . | Grades 1-2 . | Grades 3-4 . | |||
| No. of patients (%) | 744 (100) | 420 (56) | 156 (21) | 168 (23) | |
| Age, median (IQR), y | 65 (56-72) | 65 (55-73) | 66 (57-72) | 65 (56-70) | .6 |
| Karnofsky score, n (%) | <.001 | ||||
| ≥90 | 305 (41) | 195 (47) | 65 (42) | 45 (27) | |
| <90 | 437 (59) | 224 (53) | 90 (58) | 123 (73) | |
| Missing | 2 | 1 | 1 | 0 | |
| Sex, n (%) | .7 | ||||
| Male | 474 (64) | 270 (64) | 95 (61) | 109 (65) | |
| Female | 269 (36) | 150 (36) | 61 (39) | 58 (35) | |
| Missing | 1 | 0 | 0 | 1 | |
| Diagnosis, n (%) | .016 | ||||
| LBCL | 633 (85) | 363 (86) | 127 (81) | 143 (85) | |
| FL | 36 (5) | 25 (6) | 9 (6) | 2 (1) | |
| MCL | 75 (10) | 32 (8) | 20 (13) | 23 (14) | |
| Prior lines of therapy, n (%) | .002 | ||||
| <3 lines | 405 (55) | 245 (58) | 84 (54) | 76 (46) | |
| ≥3 lines | 336 (45) | 174 (42) | 72 (46) | 90 (54) | |
| Missing | 3 | 1 | 0 | 2 | |
| History of BM involvement, n (%) | .025 | ||||
| Yes | 242 (44) | 126 (40) | 54 (48) | 62 (54) | |
| No | 302 (56) | 190 (60) | 59 (52) | 53 (46) | |
| Missing | 200 | 104 | 43 | 53 | |
| Serum LDH (U/L)∗ , n (%) | <.001 | ||||
| Normal | 444 (60) | 290 (69) | 88 (56) | 66 (39) | |
| Elevated | 300 (40) | 130 (31) | 68 (44) | 102 (61) | |
| PLT,∗ median (IQR), ×109/L | 161 (106-211) | 180 (146-225) | 116 (79-176) | 83 (42-162) | <.001 |
| HEMATOTOX score,∗ n (%) | <.001 | ||||
| Low (0-1) | 442 (62) | 327 (82) | 75 (49) | 40 (25) | |
| High (≥2) | 275 (38) | 73 (18) | 79 (51) | 123 (75) | |
| Missing | 27 | 20 | 2 | 5 | |
| EASIX score,∗ median (IQR) | |||||
| EASIX | 1.14 (0.75-2.18) | 0.92 (0.68-1.38) | 1.39 (0.96-2.43) | 2.76 (1.17-8.46) | <.001 |
| Modified EASIX | 1 (0-5) | 1 (0-2) | 2 (1-6) | 5 (1-50) | <.001 |
| CAR-T product, n (%) | .004 | ||||
| Axi-cel | 360 (48) | 192 (46) | 82 (53) | 86 (51) | |
| Tisa-cel | 169 (23) | 98 (23) | 33 (21) | 38 (23) | |
| Liso-cel | 163 (22) | 111 (26) | 25 (16) | 27 (16) | |
| Brexu-cel | 52 (7) | 19 (5) | 16 (10) | 17 (10) | |
| Bridging therapy, n (%) | <.001 | ||||
| Yes | 581 (78) | 305 (73) | 127 (81) | 149 (89) | |
| No | 163 (22) | 115 (27) | 29 (19) | 19 (11) | |
| . | Overall . | Early T-ICAHT . | P value . | ||
|---|---|---|---|---|---|
| Grade 0 . | Grades 1-2 . | Grades 3-4 . | |||
| No. of patients (%) | 744 (100) | 420 (56) | 156 (21) | 168 (23) | |
| Age, median (IQR), y | 65 (56-72) | 65 (55-73) | 66 (57-72) | 65 (56-70) | .6 |
| Karnofsky score, n (%) | <.001 | ||||
| ≥90 | 305 (41) | 195 (47) | 65 (42) | 45 (27) | |
| <90 | 437 (59) | 224 (53) | 90 (58) | 123 (73) | |
| Missing | 2 | 1 | 1 | 0 | |
| Sex, n (%) | .7 | ||||
| Male | 474 (64) | 270 (64) | 95 (61) | 109 (65) | |
| Female | 269 (36) | 150 (36) | 61 (39) | 58 (35) | |
| Missing | 1 | 0 | 0 | 1 | |
| Diagnosis, n (%) | .016 | ||||
| LBCL | 633 (85) | 363 (86) | 127 (81) | 143 (85) | |
| FL | 36 (5) | 25 (6) | 9 (6) | 2 (1) | |
| MCL | 75 (10) | 32 (8) | 20 (13) | 23 (14) | |
| Prior lines of therapy, n (%) | .002 | ||||
| <3 lines | 405 (55) | 245 (58) | 84 (54) | 76 (46) | |
| ≥3 lines | 336 (45) | 174 (42) | 72 (46) | 90 (54) | |
| Missing | 3 | 1 | 0 | 2 | |
| History of BM involvement, n (%) | .025 | ||||
| Yes | 242 (44) | 126 (40) | 54 (48) | 62 (54) | |
| No | 302 (56) | 190 (60) | 59 (52) | 53 (46) | |
| Missing | 200 | 104 | 43 | 53 | |
| Serum LDH (U/L)∗ , n (%) | <.001 | ||||
| Normal | 444 (60) | 290 (69) | 88 (56) | 66 (39) | |
| Elevated | 300 (40) | 130 (31) | 68 (44) | 102 (61) | |
| PLT,∗ median (IQR), ×109/L | 161 (106-211) | 180 (146-225) | 116 (79-176) | 83 (42-162) | <.001 |
| HEMATOTOX score,∗ n (%) | <.001 | ||||
| Low (0-1) | 442 (62) | 327 (82) | 75 (49) | 40 (25) | |
| High (≥2) | 275 (38) | 73 (18) | 79 (51) | 123 (75) | |
| Missing | 27 | 20 | 2 | 5 | |
| EASIX score,∗ median (IQR) | |||||
| EASIX | 1.14 (0.75-2.18) | 0.92 (0.68-1.38) | 1.39 (0.96-2.43) | 2.76 (1.17-8.46) | <.001 |
| Modified EASIX | 1 (0-5) | 1 (0-2) | 2 (1-6) | 5 (1-50) | <.001 |
| CAR-T product, n (%) | .004 | ||||
| Axi-cel | 360 (48) | 192 (46) | 82 (53) | 86 (51) | |
| Tisa-cel | 169 (23) | 98 (23) | 33 (21) | 38 (23) | |
| Liso-cel | 163 (22) | 111 (26) | 25 (16) | 27 (16) | |
| Brexu-cel | 52 (7) | 19 (5) | 16 (10) | 17 (10) | |
| Bridging therapy, n (%) | <.001 | ||||
| Yes | 581 (78) | 305 (73) | 127 (81) | 149 (89) | |
| No | 163 (22) | 115 (27) | 29 (19) | 19 (11) | |
EASIX is calculated as follows: (LDH × creatinine)/PLT count (calculated according to Luft et al26). Modified EASIX is calculated as follows: (LDH × CRP)/PLT count (calculated according to Pennisi et al27). P values reaching statistical significance are shown in bold.
CRP, C-reactive protein; EASIX, Endothelial Activation and Stress Index; IQR, interquartile range; LDH, lactate dehydrogenase.
At time of lymphodepletion.